Researchers found that a daily dose of probiotic Lactobacillus and Bifidobacterium bacteria taken over a period of just 12 weeks is enough to yield a moderate but significant improvement in the score of Alzheimer's patients on the Mini-Mental State Examination (MMSE) scale, a standard measure of cognitive impairment.
Researchers from Kashan University of Medical Sciences and Islamic Azad University in Iran conducted a randomised, double-blind, controlled clinical trial on 52 women and men with Alzheimer's between 60 and 95 years of age.
At the beginning and the end of the 12-week experimental period, the scientists took blood samples for biochemical analyses and tested the cognitive function of the subjects with the MMSE questionnaire which includes tasks like giving the current date, counting backwards from 100 by sevens, naming objects, repeating a phrase and copying a picture.
Over the course of the study, the average score on the MMSE questionnaire significantly increased (from 8.7 to 10.6, out of a maximum of 30) in the group receiving probiotics, but not in the control group (from 8.5 to 8.0).
Also Read
"In a previous study, we showed that probiotic treatment improves the impaired spatial learning and memory in diabetic rats, but this is the first time that probiotic supplementation has been shown to benefit cognition in cognitively impaired humans," said Professor Mahmoud Salami from Kashan University.
Treatment with probiotics also resulted in lower levels of triglycerides, Very Low Density Lipoprotein (VLDL), high-sensitivity C-Reactive Protein (hs-CRP) in the blood of the Alzheimer patients, and likewise a reduction in two common measures (called "Homeostatic Model Assessment", HOMA-IR and HOMA-B) of insulin resistance and the activity of the insulin-producing cells in the pancreas.
The study was published in the journal Frontiers in Aging Neuroscience.
Disclaimer: No Business Standard Journalist was involved in creation of this content